Progesterone increases serum CA-125 in endometriosis.
Serum level of CA-125 was monitored up to 48 hours after injection of 125 mg P-in-oil into patients with or without endometriosis in the follicular phase of their menstrual cycle. Circulating CA-125 levels remained unchanged at around 5 U/ml during the observation period in patients without endometriosis; however, a significant elevation was observed at 30 hours after injection in those patients with endometriosis (from 19.6 U/ml before injection to 30.0 U/ml at 30 hours after injection, P less than 0.05).
Ozasa
H
H
Noda
Y
Y
Mori
T
T
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D004715:Endometriosis / Q000097:blood / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D004958:Estradiol / Q000097:blood; D005260:Female; D005498:Follicular Phase; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000494:pharmacology; D007273:Injections, Intramuscular; D008875:Middle Aged; D011374:Progesterone / Q000097:blood / Q000494:pharmacology*; D011863:Radioimmunoassay; D013997:Time Factors; D014594:Uterine Neoplasms / Q000097:blood / Q000276:immunology*
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate; D011374:Progesterone; D004958:Estradiol